Neumora Therapeutics stockholders elect directors, approve option repricing and reverse split at 2025 annual meeting

Neumora Therapeutics, Inc.

Elected Alaa Halawa (105,795,914 votes for) and Maykin Ho (114,262,481 votes for) as Class II directors.
Ratified Ernst & Young as independent auditor for fiscal 2025 with 135,734,870 votes for.
Approved repricing of certain outstanding stock options under 2020 and 2023 equity plans (101,589,422 for).
Approved reverse stock split at ratio between 1:5 and 1:30, as determined by board (134,256,461 for).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.